

HEMODYNAMIC DISORDERS, THROMBOEMBOLISM, AND SHOCK 2





 NORMAL HEMOSTASIS COMPRISES A SERIES OF REGULATED PROCESSES THAT CULMINATE IN THE FORMATION OF A <u>BLOOD CLOT</u> THAT LIMITS BLEEDING FROM AN <u>INJURED VESSEL</u>.


 THE PATHOLOGIC COUNTERPART OF HEMOSTASIS IS THROMBOSIS, THE FORMATION OF BLOOD CLOT (THROMBUS) WITHIN NON-TRAUMATIZED, INTACT VESSELS.



NORMAL HEMOSTASIS

 HEMOSTASIS IS PROCESS INVOLVING <u>PLATELETS</u>, <u>CLOTTING FACTORS</u>, AND <u>ENDOTHELIUM</u> THAT OCCURS AT THE SITE OF VASCULAR INJURY AND CULMINATES IN THE FORMATION OF A BLOOD CLOT, WHICH SERVES TO PREVENT OR LIMIT THE EXTENT OF BLEEDING.

Major Components of Hemostasis






 \bigcirc

2.Clotting factors

3.Endothelium


THE GENERAL SEQUENCE OF EVENTS LEADING TO HEMOSTASIS AT A SITE OF VASCULAR INJURY INCLUDE: I . PRIMARY HEMOSTASIS

- <u>1. ARTERIOLAR VASOCONSTRICTION</u>:
- occurs immediately and markedly reduces blood flow to the injured area.
- it is mediated by reflex neurogenic mechanisms.
- it is augmented by endothelin, a potent endothelium-derived vasoconstrictor.
- this effect is transient, however, bleeding would resume if not followed by activation of platelets and coagulation factors.
 A. VASOCONSTRICTION





● THE FORMATION OF THE PLATELET PLUG.




- platelets play a critical role in hemostasis by forming the primary plug that initially seals vascular defects and by providing a surface that binds and concentrates activated coagulation factors.
- platelets are disc-shaped anucleate cell fragments that are shed from megakaryocytes in the bone marrow into the bloodstream.

- Their function depends on several factors including:
- Glycoprotein receptors.

LATELETS


- A contractile cytoskeleton
- Awo types of cytoplasmic granules.
- <u>α-granules</u> have the adhesion molecule p-selectin, and contain proteins involved in coagulation.
- dense (or δ) granules contain ADP and ATP , ionized calcium, serotonin, and epinephrine.



PLATELETS UNDERGO A SEQUENCE OF REACTIONS AFTER A TRAUMATIC VASCULAR INJURY THAT CULMINATE IN THE FORMATION OF A PLATELET PLUG

• <u>1. PLATELET ADHESION:</u>

 is mediated via interactions with vwf, which acts as a bridge between the platelet surface receptor glycoprotein ib (gpib) and exposed collagen.







- <u>A. CHANGES IN SHAPE</u> from smooth discs to spiky "sea urchins" with greatly increased surface area.
 - alterations in glycoprotein iib/iiia that increase its affinity for fibrinogen
 - the translocation of negatively charged phospholipids to the platelet surface
 - <u>B. SECRETION OF GRANULE CONTENTS, e.g.</u>
 - ✓ THROMBIN: ACTIVATES PLATELETS
 - ✓ ADP: CREATE AN ADDITIONAL ROUNDS OF PLATELET ACTIVATION.
 - ✓ THROMBOXANE A2 (TXA2): A POTENT INDUCER OF PLATELET AGGREGATION.


3. PLATELET AGGREGATION FOLLOWS THEIR ACTIVATION.

 The conformational change in glycoprotein iib/iiia allows binding of fibrinogen that forms bridges between adjacent platelets, leading to their aggregation.

✓ fibrinogen cause reversible aggregation


✓ thrombin cause irreversible aggregation (converts fibrinogen into insoluble fibrin).

 \checkmark cytoskeleton cause contraction of the plug.





- DEPOSITION OF FIBRIN.
 - VASCULAR INJURY EXPOSES TISSUE FACTOR AT THE SITE OF INJURY.
 - TISSUE FACTOR BINDS AND ACTIVATES FACTOR <u>VII</u>, SETTING IN MOTION A CASCADE OF REACTIONS THAT CULIMINATES IN THROMBIN GENERATION.




• MI. CLOT STABILIZATION AND RESORPTION:

 POLYMERIZED FIBRIN AND PLATELET AGGREGATES UNDERGO CONTRACTION TO FORM A SOLID, PERMANENT PLUG THAT PREVENTS FURTHER HEMORRHAGE.

 ENTRAPPED RED CELLS AND LEUKOCYTES ARE ALSO FOUND IN HEMOSTATIC PLUGS, IN PART DUE TO ADHERENCE OF LEUKOCYTES TO P-SELECTIN EXPRESSED ON ACTIVATED PLATELET

 AT THIS STAGE, COUNTERREGULATORY MECHANISMS (E.G., TISSUE PLASMINOGEN ACTIVATOR, T-PA MADE BY ENDOTHELIAL CELLS) ARE SET INTO MOTION THAT LIMIT CLOTTING TO THE SITE OF INJURY, AND EVENTUALLY LEAD TO CLOT RESORPTION AND TISSUE REPAIR.

D. CLOT RESORPTION






 the coagulation cascade is a series of amplifying enzymatic reactions that lead to the deposition of <u>an insoluble</u> fibrin clot.

each reaction step involves an <u>enzyme</u> (an activated coagulation factor), a <u>substrate</u> (an inactive proenzyme form of a coagulation factor), and a <u>cofactor</u> (a reaction accelerator).

 these components are assembled on a negatively charged phospholipid surface, which is provided by activated platelets. assembly of reaction complexes also depends on calcium





Mnemonic for Vitamin K Dependent Clotting Factors

"Two plus seven is nine NOT ten!"

27910

vitamin K antagonists


Coagulation cascade has traditionally been divided into the extrinsic and intrinsic pathways



- <u>1.THE PROTHROMBIN TIME (PT)</u>
- ASSAY ASSESSES THE FUNCTION OF THE PROTEINS IN THE <u>EXTRINSIC PATHWAY (FACTORS VII,</u> X, V, II (PROTHROMBIN), AND FIBRINOGEN).
- THE PARTIAL THROMBOPLASTIN TIME (PTT)
- ASSAY SCREENS THE FUNCTION OF THE PROTEINS IN THE <u>INTRINSIC PATHWAY</u> (FACTORS XII, XI, IX, VIII, X, V, II, AND FIBRINOGEN.

AMONG THROMBIN'S MOST IMPORTANT ACTIVITIES ARE THE FOLLOWING:

- (1) CONVERSION OF FIBRINOGEN INTO CROSSLINKED FIBRIN.
- THROMBIN DIRECTLY CONVERTS SOLUBLE FIBRINOGEN INTO FIBRIN MONOMERS THAT
 POLYMERIZE INTO AN INSOLUBLE FIBRIL.
- <u>2.PLATELET ACTIVATION.</u>
- <u>4. ANTI-COAGULANT EFFECTS.</u>
- ENCOUNTERING NORMAL ENDOTHELIUM, THROMBIN CHANGES FROM A PROCOAGULANT TO AN ANTICOAGULANT.



FACTORS THAT LIMIT COAGULATION.

- COAGULATION MUST BE RESTRICTED TO THE SITE OF VASCULAR INJURY TO PREVENT DANGEROUS CONSEQUENCES THROUGH:
- <u>1.SIMPLE DILUTION:</u>
- BLOOD FLOWING AT THE SITE OF INJURY WASHES OUT ACTIVATED COAGULATION FACTORS, WHICH ARE RAPIDLY REMOVED BY THE LIVER.
- 2.REQUIREMENT FOR NEGATIVELY CHARGED PHOSPHOLIPIDS
- <u>3. FIBRINOLYTIC CASCADE</u>
- THROUGH THE ENZYMATIC ACTIVITY OF PLASMIN, WHICH BREAKS DOWN FIBRIN AND INTERFERES WITH ITS POLYMERIZATION.

fibrinolytic cascade

Plasminogen activators

Tissue plasminogen activator (tPA), urokinase, streptokinase staphylokinase, vampire bat PA

PAI - 1 (inhibits tPA, present in blood in small concentration)

Cleave plasminogen into active plasmin

Plasminogen Plasmin

Fibrin

Degrades fibrin clot, core of thrombus


α_2 -antiplasmin

(physiological inhibitor of plasmin present in blood in concentration 6-8X exceeding therapeutic dose of plasmin)

Fibrin degradation products



 AN ELEVATED LEVEL OF BREAKDOWN PRODUCTS OF FIBRINOGEN (D-DIMERS) ARE A USEFUL CLINICAL MARKERS OF SEVERAL THROMBOTIC STATES





 THE BALANCE BETWEEN THE ANTICOAGULANT AND PROCOAGULANT ACTIVITIES OF ENDOTHELIUM OFTEN DETERMINES WHETHER CLOT FORMATION, PROPAGATION, OR DISSOLUTION OCCURS.

.PLATELET INHIBITORY EFFECTS:

SERVE AS A BARRIER THAT SHIELDS PLATELETS FROM SUBENDOTHELIAL VWF AND COLLAGEN.

- ✓ RELEASES A NUMBER OF FACTORS THAT INHIBIT PLATELET ACTIVATION AND AGGREGATION. AMONG THE MOST IMPORTANT ARE PROSTACYCLIN (PGI2), NITRIC OXIDE (NO).
- ✓ ENDOTHELIAL CELLS BIND AND ALTER THE ACTIVITY OF THROMBIN, WHICH IS ONE OF THE MOST POTENT ACTIVATORS OF PLATELETS.
- 2. ANTICOAGULANT EFFECTS.
- NORMAL ENDOTHELIUM SHIELDS COAGULATION FACTORS FROM TISSUE FACTOR IN VESSEL WALLS
 AND EXPRESSES MULTIPLE FACTORS THAT ACTIVELY OPPOSE COAGULATION:
- MOST NOTABLY <u>THROMBOMODULIN, ENDOTHELIAL PROTEIN C RECEPTOR, HEPARIN-LIKE MOLECULES,</u> <u>AND TISSUE FACTOR PATHWAY INHIBITOR.</u>

